Mount Sinai and SOPHiA GENETICS Partner on Precision Cancer Care

Collaboration aims to advance AI-driven personalized cancer treatment at leading academic health system.

Apr. 16, 2026 at 1:08pm

Got story updates? Submit your updates here. ›

An abstract, ghostly X-ray image revealing the intricate internal structure of a cancer cell, conceptually representing the advanced genomic analysis capabilities that will be applied through the Mount Sinai and SOPHiA GENETICS collaboration.Advanced AI-powered genomic analysis will enable Mount Sinai to provide more personalized, data-driven cancer treatments for its diverse patient population.San Diego Today

SOPHiA GENETICS, a global leader in AI-driven precision medicine, has announced a collaboration with the Mount Sinai Health System, one of the top academic medical centers in the United States. The partnership will focus on leveraging SOPHiA's AI technology to enhance personalized cancer care and treatment at Mount Sinai.

Why it matters

This collaboration represents an important step forward in bringing cutting-edge precision oncology tools to a major healthcare provider. By integrating SOPHiA's AI-powered genomic analysis platform, Mount Sinai can provide more tailored, data-driven cancer treatments to its diverse patient population.

The details

Under the agreement, Mount Sinai will implement SOPHiA's suite of AI-based genomic analysis solutions across its oncology programs. This will enable the health system to better identify genetic biomarkers, match patients to targeted therapies, and monitor treatment response. The partnership will also involve joint research initiatives to further advance precision cancer care.

  • The collaboration was announced on April 16, 2026.

The players

SOPHiA GENETICS

A global leader in AI-driven precision medicine and a publicly traded company on the NASDAQ stock exchange.

Mount Sinai Health System

One of the leading academic medical centers in the United States, known for its innovative approaches to healthcare.

Got photos? Submit your photos here. ›

What they’re saying

“We are excited to partner with Mount Sinai, a renowned healthcare leader, to advance the adoption of precision oncology and improve outcomes for cancer patients.”

— Jurgi Camblong, CEO and Co-Founder, SOPHiA GENETICS

“This collaboration with SOPHiA GENETICS will enable us to leverage the power of AI to deliver more personalized, data-driven cancer care to our diverse patient population.”

— Dennis S. Charney, Dean, Icahn School of Medicine at Mount Sinai

What’s next

The partnership between Mount Sinai and SOPHiA GENETICS is expected to be implemented across the health system's oncology programs in the coming months, with plans for ongoing joint research initiatives to further advance precision cancer care.

The takeaway

This collaboration represents a significant step forward in bringing cutting-edge precision oncology tools to a leading academic medical center, with the potential to improve cancer treatment outcomes for patients through more personalized, data-driven care.